The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration

The clinical pharmacogeneticist: An emerging regulatory scientist at the US Food and Drug Administration

Bibliographic Details
Main Authors:	Zineh Issam, Woodcock Janet
Format:	Article
Language:	English
Published:	BMC 2010-04-01
Series:	Human Genomics
Online Access:	http://www.humgenomics.com/content/4/4/221

Similar Items

US Food and Drug Administration embraces using innovation to identify optimized dosages for patients with cancer
by: Stacy S. Shord, et al.
Published: (2023-11-01)

Quantitative Systems Pharmacology: A Regulatory Perspective on Translation
by: Issam Zineh
Published: (2019-06-01)

Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs
by: Robert N. Schuck, et al.
Published: (2019-05-01)

U.S. Food and Drug Administration: Review for the Emergency Physician of Approval Process and Limitations
by: Nadia Zuabi, et al.
Published: (2016-11-01)

Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980–2022
by: Enrique Seoane-Vazquez, et al.
Published: (2024-02-01)

Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
by: Fei Liang, et al.
Published: (2020-08-01)

A U.S. Food and Drug Administration perspective on cannabis research and drug development
by: Cassandra L. Taylor, et al.
Published: (2023-10-01)

Severe malaria, pascalian therapeutics, and the US Food and Drug Administration (FDA)
by: White, NJ, et al.
Published: (2022)

Why the Watchdog Won’t Bite: U.S. Food and Drug Administration Challenges
by: Joe Lex
Published: (2016-11-01)

Vaccines, Pharmaceutical Products, and Bioterrorism: Challenges for the U.S. Food and Drug Administration
by: Kathryn C. Zoon
Published: (1999-08-01)

Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations
by: Yassine Kamal Lyauk, et al.
Published: (2019-09-01)

Prescription Drug Promotion from 2001-2014: Data from the U.S. Food and Drug Administration.
by: Helen W Sullivan, et al.
Published: (2016-01-01)

Compromise or capitulation? US Food and Drug Administration jurisdiction over tobacco products.
by: Stanton A Glantz, et al.
Published: (2009-07-01)

A Proposed Framework for Patient-Focused Policy at the U.S. Food and Drug Administration
by: Carrie M. Kuehn
Published: (2019-08-01)

Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.
by: Robert K M Choy, et al.
Published: (2020-07-01)

Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings.
by: Shelley K White, et al.
Published: (2023-01-01)

Regulatory scripting: Stakeholder participation in food and drug administration medical device advisory meetings
by: Shelley K. White, et al.
Published: (2023-01-01)

Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01)

Pediatric dosing for locally acting drugs in submissions to the U.S. Food and Drug Administration between 2002 and 2020
by: Gelareh A. Abulwerdi, et al.
Published: (2023-10-01)

Drug-induced tooth discoloration: An analysis of the US food and drug administration adverse event reporting system
by: Jun Wang, et al.
Published: (2023-04-01)

The US Food and Drug Administration provides a pathway for licensing vaccines for global diseases.
by: Michael J Brennan
Published: (2009-07-01)

Comparison of hydroxyethyl starch regulatory summaries from the Food and Drug Administration and the European Medicines Agency
by: Christian J. Wiedermann, et al.
Published: (2017-12-01)

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
by: Joshua D. Wallach, et al.
Published: (2019-06-01)

Endovascular Strategies for Aortic Arch When US Food and Drug Administration–Approved Devices Are Not Available
by: Gabrielle Sutton, MS, et al.
Published: (2024-03-01)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
by: Ying Zhang, et al.
Published: (2023-07-01)

Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel
by: Marwan N. Sabbagh, et al.
Published: (2023-01-01)

Approval of raxibacumab for the treatment of inhalation anthrax under the US Food and Drug Administration Animal rule
by: Chia-Wei eTsai, et al.
Published: (2015-12-01)

Magnitude of effect and sample size justification in trials supporting anti-cancer drug approval by the US Food and Drug Administration
by: Michelle B. Nadler, et al.
Published: (2024-01-01)

Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018
by: Min Fan, et al.
Published: (2022-01-01)

Hermeneutics of Food and Drug Regulatory Policy
by: Joseph A. Tuminello, III
Published: (2020-12-01)

A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration
by: Ulrich‐P. Rohr, et al.
Published: (2023-09-01)

Shortened Positive and Negative Symptom Scale as an Alternate Clinical Endpoint for Acute Schizophrenia Trials: Analysis from the US Food & Drug Administration
by: Mathangi Gopalakrishnan, et al.
Published: (2021-03-01)

US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
by: Haidar Al Saffar, et al.
Published: (2023-06-01)

The life cycles of six multi-center adaptive clinical trials focused on neurological emergencies developed for the Advancing Regulatory Science initiative of the National Institutes of Health and US Food and Drug Administration: Case studies from the Adaptive Designs Accelerating Promising Treatments Into Trials Project
by: Timothy C Guetterman, et al.
Published: (2017-10-01)

Regulatory landscape analysis of Myanmar Food and Drug Administration based on the World Health Organization Global benchmarking tool
by: Ei Ei Chaw, et al.
Published: (2022-09-01)

Food and Drug Administration approvals in phase 3 Cancer clinical trials
by: Joseph Abi Jaoude, et al.
Published: (2021-06-01)

Food protein chemistry : an introduction for food scientists /
by: 360660 Regenstein, Joe M., et al.
Published: (1984)

A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study
by: Joel Lexchin
Published: (2021-12-01)

Association between expedited review designations and the US or global burden of disease for drugs approved by the US Food and Drug Administration, 2010–2019: a cross-sectional analysis
by: Matthew J Jackson, et al.
Published: (2024-03-01)

Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint
by: Brian E. Lacy, et al.
Published: (2018-05-01)